The primary objective of the registry is to estimate the prevalence of major congenital malformations among pregnant individuals with IBD who are exposed to an IBD pharmacotherapy during pregnancy.

The primary objective of this research is to evaluate specific and non-specific effects of hypnotherapy. 

The secondary objective is to evaluate the efficacy of group-format gut-directed hypnotherapy delivered via telehealth for managing gastrointestinal health.

The objective of the BOOM-IBD2 clinical trial is to evaluate the effectiveness of an investigational nerve stimulation (neuromodulation) device for ulcerative colitis (UC). This treatment involves implanting a small electronic device that delivers mild electrical pulses to a nerve near the tailbone. The study will assess the impact of this therapy on bowel urgency, quality of life, inflammation, and other measures over a 12-month period through a combination of in-person and virtual visits.

To create a high-risk for inflammatory bowel disease research cohort, by enrolling individuals who have a first-degree relative (parent sibling, or child) with inflammatory bowel disease (IBD; including Crohn’s disease, ulcerative colitis, or IBD unclassified/indeterminate colitis), but who do not have one of these diseases themselves.

To monitor behaviors, diet, and biomarkers of IBD in these unaffected first-degree relatives over time, to better understand how to predict and prevent the development of IBD in high-risk individuals.

To determine the effect of dual targeted therapy with an anti-integrin (VDZ) and a JAK inhibitor (TOF) on clinical remission.

An Open-Label, Phase 4 Study to Evaluate the Efficacy and Safety of Dual Targeted Therapy with Vedolizumab Intravenous (IV) and Adalimumab Subcutaneous (SC) or Vedolizumab IV and Ustekinumab IV/SC in Moderate to Severe Crohn’s Disease (CD).

The purpose of this study is to continuously monitor a patient's IBD biomarkers with the non-invasive IBD Aware wearable device to determine its effectiveness in monitoring IBD inflammation. We also aim to understand how these inflammatory biomarkers relate to your symptoms. By participating, you'll help us enhance the way we monitor and manage IBD. 

The Cimzia Pregnancy Exposure Registry is following pregnant women who have been treated with Cimzia during pregnancy and comparing them to pregnant women who were not exposed to Cimzia. Both groups of women and their babies will be followed up to 1 year after delivery. The goal is to determine the possible effect of Cimzia and the diseases it treats on pregnancy and infant outcomes.

To understand the most important priorities of IBD patients who need surgery and quantify the reasons why patients consider delaying surgery, with potential reasons including, but not limited to lack of psychosocial support, gaps in knowledge, social stigma, burden to daily life, financial reasons, concerns about fertility, and mental well-being.

The purpose of this trial is to:

• To investigate how well the treatment with trial drug BI 706321 (in addition to ustekinumab) can improve the symptoms of CD
• To investigate the safety of BI 706321 and how you tolerate BI 706321
• To collect your blood and assess the amount of BI 706321 in the body (called pharmacokinetics or PK, meaning how your body absorbs and distributes BI 706321 and how BI 706321 leaves the body) and biomarkers (how other proteins in your body are influenced by BI 706321).